PRIALT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prialt, and when can generic versions of Prialt launch?
Prialt is a drug marketed by Tersera and is included in one NDA. There are three patents protecting this drug.
This drug has six patent family members in four countries.
The generic ingredient in PRIALT is ziconotide acetate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ziconotide acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Prialt
Prialt was eligible for patent challenges on December 28, 2008.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 1, 2024. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PRIALT?
- What are the global sales for PRIALT?
- What is Average Wholesale Price for PRIALT?
Summary for PRIALT
| International Patents: | 6 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 31 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,219 |
| Drug Prices: | Drug price information for PRIALT |
| What excipients (inactive ingredients) are in PRIALT? | PRIALT excipients list |
| DailyMed Link: | PRIALT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PRIALT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PRIALT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Albany Medical College | Phase 4 |
| Aaron Boster | Phase 4 |
| Jazz Pharmaceuticals |
Pharmacology for PRIALT
| Drug Class | N-type Calcium Channel Antagonist |
| Mechanism of Action | N-Calcium Channel Receptor Antagonists |
US Patents and Regulatory Information for PRIALT
PRIALT is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PRIALT is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting PRIALT
Method for administering omega-conopeptide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ANALGESIA
Method for administering omega-conopeptide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PAIN
Method for administering omega-conopeptide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ANALGESIA
Method for administering omega-conopeptide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PAIN
Method for administering .omega.-conopeptide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-002 | Dec 28, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-003 | Dec 28, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-002 | Dec 28, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-001 | Dec 28, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-003 | Dec 28, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-004 | Dec 28, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PRIALT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-004 | Dec 28, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-003 | Dec 28, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-001 | Dec 28, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-002 | Dec 28, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-001 | Dec 28, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | PRIALT | ziconotide acetate | INJECTABLE;INTRATHECAL | 021060-002 | Dec 28, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PRIALT
See the table below for patents covering PRIALT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2011173931 | METHOD FOR REDUCING PAIN | ⤷ Sign Up |
| Hong Kong | 1013832 | ⤷ Sign Up | |
| Canada | 2540895 | METHODE DE SOULAGEMENT DE LA DOULEUR (METHOD FOR REDUCING PAIN) | ⤷ Sign Up |
| Singapore | 50624 | Methods of producing analgesia and enhancing opiate analgesia | ⤷ Sign Up |
| Japan | 2838073 | ⤷ Sign Up | |
| Canada | 2224795 | COMPOSITIONS ET FORMULATIONS PERMETTANT DE PRODUIRE UNE ANALGESIE ET D'INHIBER LA PROGRESSION DE TROUBLES LIES A DES DOULEURS NEUROPATHIQUES (COMPOSITIONS AND FORMULATIONS FOR PRODUCING ANALGESIA AND FOR INHIBITING PROGRESSION OF NEUROPATHIC PAIN DISORDERS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PRIALT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0835126 | 289 | Finland | ⤷ Sign Up | |
| 0835126 | 300201 | Netherlands | ⤷ Sign Up | 300201, 20160626, EXPIRES: 20200220 |
| 0835126 | C00835126/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ZICONOTIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56855 11.04.2006 |
| 0835126 | SPC019/2005 | Ireland | ⤷ Sign Up | SPC019/2005: 20060407, EXPIRES: 20200220 |
| 0835126 | 91181 | Luxembourg | ⤷ Sign Up | 91181, EXPIRES: 20200221 |
| 0835126 | SPC/GB05/033 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ZICONOTIDE, OPTIONALLY IN THE FORM OF A SALT WITH A PHARMACEUTICALLY ACCEPTABLE ACID, INCLUDING ZICONOTIDE ACETATE; REGISTRATION NO/DATE: EU/1/04/302/001 - 003 20050224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
